Dr Min-Han Tan is the Founding CEO of Lucence Diagnostics. Lucence is an international genomic medicine company headquartered in Singapore, with offices in San Francisco, Suzhou and Hong Kong, providing physicians advanced cancer diagnostics services through a CAP, ISO15189 and CLIA-licensed central clinical laboratory.A trained medical oncologist and clinical cancer geneticist, Dr Tan received his MBBS in 1998 and completed his cancer specialist training at NCCS in 2003. He obtained his PhD in molecular epidemiology and biostatistics from National University of Singapore. Dr Tan completed a clinical cancer genetics fellowship at the Cleveland Clinic. In 2011, he joined the Agency for Science, Technology and Research (A*STAR) in Singapore to lead the Laboratory of Systems Medicine. Dr Tan subsequently founded Lucence in 2016 to commercialize the cancer diagnostic technology his lab developed at A*STAR.Dr Tan has published over 100 original research publications in journals and filed more than 12 patents. He is recognized internationally for his landmark discovery of circulating tumor-endothelial cell clusters in the blood of cancer patients, which overturned a 50-year scientific dogma. As a clinical cancer geneticist, Dr Tan reported the international diagnostic criteria and lifetime cancer risks for Cowden syndrome, a hereditary breast cancer syndrome. He led a breast cancer screening research study involving over 29,000 individuals prospectively followed up over 20 years.For his track record of disruptive innovation in research and clinical medicine, Dr Tan has been recognized with awards from the American Society of Clinical Oncology, the European Society of Medical Oncology and the Association of Southeast Asian Nations. He was elected Fellow of the Royal College of Physicians Edinburgh in 2015 and received the A*STAR Outstanding Scientist-Entrepreneur Award in 2018.